	Application No.	Applicant(s)
Notice of Allowability	09/932,731	ROTH ET AL.
	Examiner	Art Unit
	Robert Sellers	1712
The MAILING DATE of this communication ap All claims being allowable, PROSECUTION ON THE MERITS herewith (or previously mailed), a Notice of Allowance (PTOL-8 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT of the Office or upon petition by the applicant. See 37 CFR 1.3	IS (OR REMAINS) CLOSED in 85) or other appropriate communication is s	n this application. If not included unication will be mailed in due course. THIS
 ∴ This communication is responsive to the amendment file ∴ The allowed claim(s) is/are 9-41. ∴ The drawings filed on are accepted by the Examination for the examination of the	iner. v under 35 U.S.C. § 119(a)-(d)	or (f).
Certified copies of the priority documents have		
2. Certified copies of the priority documents ha	• • • • • • • • • • • • • • • • • • • •	
3. Copies of the certified copies of the priority		d in this national stage application from the
International Bureau (PCT Rule 17.2(a)).		
 Certified copies not received; Acknowledgment is made of a claim for domestic priority reference was included in the first sentence of the speci 		
(a) The translation of the foreign language provisional	• •	
Acknowledgment is made of a claim for domestic priority in the first sentence of the specification or in an Applicat		or 121 since a specific reference was included
Applicant has THREE MONTHS FROM THE "MAILING DATE" below. Failure to timely comply will result in ABANDONMENT	of this communication to file a of this application. THIS THR	reply complying with the requirements noted EE-MONTH PERIOD IS NOT EXTENDABLE
 A SUBSTITUTE OATH OR DECLARATION must be sul INFORMAL PATENT APPLICATION (PTO-152) which g 		
 CORRECTED DRAWINGS (as "replacement sheets") n (a) ☐ including changes required by the Notice of Draftsp 1) ☐ hereto or 2) ☐ to Paper No 		v (PTO-948) attached
(b) ☐ including changes required by the proposed drawin	g correction filed, whic	h has been approved by the Examiner.
(c) ☐ including changes required by the attached Examin	er's Amendment / Comment or	in the Office action of Paper No
Identifying indicia such as the application number (see 37 CFI each sheet. Replacement sheet(s) should be labeled as such i		
 DEPOSIT OF and/or INFORMATION about the de attached Examiner's comment regarding REQUIREMENT FOR 		
Attachment(s)		
1☐ Notice of References Cited (PTO-892)		ormal Patent Application (PTO-152)
2 Notice of Draftperson's Patent Drawing Review (PTO-948		mmary (PTO-413), Paper No. <u>1103</u> .
3⊠ Information Disclosure Statements (PTO-1449 or PTO/SB Paper 1949, 9/15/03.	7⊠ Examiner's A	Amendment/Comment
4 Examiner's Comment Regarding Requirement for Deposit of Biological Material	8⊠ Examiner's S 9∏ Other	Statement of Reasons for Allowance
		Robert Sellers Primary Examiner Art Unit: 1712

Application/Control Number: 09/932,731

Art Unit: 1712

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Kristin Neuman on December 1, 2003.

The application has been amended as follows:

Change the title to: --EPOXY ACRYLATE OF AROMATIC BIPHENOL-ADVANCED EPOXY RESIN REACTED WITH ANHYDRIDE--.

Specification, page 1, line 1, insert --This application is a continuation of application no. 08/268,094 filed June 28, 1994, abandoned.--.

Specification, page 1, line 2; page 2, line 12; page 3, line 2; page 9, line 16; page 10, line 19; page 13, line 16; page 27, line 23 and page 28, lines 4 and 21:

Delete each occurrence of "novel".

Claim 9, line 3, formula IV, amend "N" to --n--.

Cancel claims 1-4 and 7.

Replace the abstract with the following new one presented on a separate page.

The following is an examiner's statement of reasons for allowance:

The insertion into claims 9, 10, 25, 26 and 41 of the limitation suggested on page 4, the last paragraph of the non-Final rejection mailed February 27, 2003 overcomes the 35 U.S.C. 112, first paragraph, rejection.

The affirmative steps of mixing of the carboxyl group-containing epoxy acrylate of formula IV with a photoinitiator in the method of preparation of a photoresist formulation of independent claim 25 resolves the 35 U.S.C. 112, second paragraph, rejection.

The 35 U.S.C. 102(a) or 103(a) rejection over Japanese Patent No. 5-32746 is rescinded due to the limitation of the cyclic anhydride of a polycarboxylic acid represented by R₃ in formula IV to succinic anhydride which is not recited.

The Japanese patent on page 16, lines 3-4; page 24, Synthetic Example 6; page 25, Synthetic Examples 7 and 8; page 26 Synthetic Example 9; and pages 26-27, Synthetic Example 10 discloses and shows maleic, phthalic, tetrahydrophthalic or hexahydrophthalic acid or anhydride. There is no motivation to employ the claimed succinic anhydride as the polycarboxylic acid anhydride reactant for the epoxy acrylate of the Japanese patent to produce the carboxyl group-containing epoxy acrylate of formula IV.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

(703) 308-2399 (Fax no. (703) 872-9306) Monday to Friday from 9:30 to 6:00 EST

rs 11/19/03

ROBERT E. SELLERS II PRIMARY EXAMINER Application/Control Number: 09/932,731

Art Unit: 1712

-- Abstract of the Disclosure

A carboxyl group-containing epoxy acrylate is prepared by the reaction of an epoxy resin advanced with an aromatic biphenol compound which is reacted with a polycarboxylic acid anhydride in the presence or absence of a catalyst and a polymerization inhibitor at an elevated termperature. The carboxyl group-containing epoxy acrylate is mixed with a photoinitiator to obtain a photoresist formulation.--.